Early studies demonstrated that depletion of CD4+CD25+ Treg with antibodies, targeting the IL‐2 receptor (CD25) restored anti‐tumor immunity in a variety of pre‐clinical models 13, 14, 15, 16, 17, 18, 19. Here, CD4 is linked to neoplasm.